Abstract
Alzheimer’s disease (AD) is a neurodegenerative disorder that severely jeopardizes the health of aging populations all over the world. According to the amyloid cascade hypothesis, the pathological progression of AD is associated with the formation of amyloid plaques in the brain, resulting from the aggregation of amyloid-β (Aβ) peptides. Over the past few years, vast efforts have been dedicated to the development of amyloid probes and inhibitors for the diagnosis and effective treatment of AD. We review here recent advancements in luminescent probes for the detection of Aβ peptide and fibrils, and the current development of small molecule inhibitors of Aβ aggregation. We also highlight the key features in each specific example, as well as review new ideas and strategies that are crucial for researchers in this field.
Keywords: Aggregation inhibitor, Alzheimer’s disease, beta-amyloid, luminescent probe, therapeutics agents, cholinergic neurons, trauma, amyloid cascade.
Current Alzheimer Research
Title:Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation
Volume: 9 Issue: 7
Author(s): Dik-Lung Ma, Daniel Shiu-Hin Chan, Victor Pui-Yan Ma, Ka-Ho Leung, Hai-Jing Zhong and Chung-Hang Leung
Affiliation:
Keywords: Aggregation inhibitor, Alzheimer’s disease, beta-amyloid, luminescent probe, therapeutics agents, cholinergic neurons, trauma, amyloid cascade.
Abstract: Alzheimer’s disease (AD) is a neurodegenerative disorder that severely jeopardizes the health of aging populations all over the world. According to the amyloid cascade hypothesis, the pathological progression of AD is associated with the formation of amyloid plaques in the brain, resulting from the aggregation of amyloid-β (Aβ) peptides. Over the past few years, vast efforts have been dedicated to the development of amyloid probes and inhibitors for the diagnosis and effective treatment of AD. We review here recent advancements in luminescent probes for the detection of Aβ peptide and fibrils, and the current development of small molecule inhibitors of Aβ aggregation. We also highlight the key features in each specific example, as well as review new ideas and strategies that are crucial for researchers in this field.
Export Options
About this article
Cite this article as:
Ma Dik-Lung, Shiu-Hin Chan Daniel, Pui-Yan Ma Victor, Leung Ka-Ho, Zhong Hai-Jing and Leung Chung-Hang, Current Advancements in Aβ Luminescent Probes and Inhibitors of Aβ Aggregation, Current Alzheimer Research 2012; 9 (7) . https://dx.doi.org/10.2174/156720512802455377
DOI https://dx.doi.org/10.2174/156720512802455377 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cranberry as Promising Natural Source of Potential Anticancer Agents: Current Evidence and Future Perspectives
Anti-Cancer Agents in Medicinal Chemistry Periodontal Disease and Potential Association with Systemic Diseases and Conditions (Mini-review)
Applied Clinical Research, Clinical Trials and Regulatory Affairs Addressing Alzheimer’s Disease and Cognitive Loss through Autophagy
Current Neurovascular Research The Etiology of Hypertension in the Metabolic Syndrome Part Two: The Gene-Environment Interaction
Current Vascular Pharmacology Emerging Role of Antioxidants in the Protection of Uveitis Complications
Current Medicinal Chemistry Vascular, Oxidative, and Synaptosomal Abnormalities During Aging and the Progression of Type 2 Diabetes
Current Neurovascular Research Milestones in Antihypertensive Drug Treatment
Current Pharmaceutical Design Advances in L-Type Calcium Channel Structures, Functions and Molecular Modeling
Current Medicinal Chemistry The Etiology of Hypertension in the Metabolic Syndrome Part One: An Introduction to the History, the Concept and the Models
Current Vascular Pharmacology Hereditary Haemorrhagic Telangiectasia: A Rare Disease As A Model for the Study of Human Atherosclerosis
Current Pharmaceutical Design MicroRNA Expression in Coronary Artery Disease
MicroRNA MMP Inhibitors in Cardiac Diseases: An Update
Recent Patents on Cardiovascular Drug Discovery Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients
Current Vascular Pharmacology The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?
Current Cardiology Reviews Interstitial Lung Disease Associated with Collagen Vascular Disease
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Extracellular Matrix, Integrins, and Mesenchymal Cell Function in the Airways
Current Drug Targets A Rationale for Combined Therapy with a Calcium Channel Blocker and a Statin: Evaluation of Basic and Clinical Evidence
Current Drug Targets - Cardiovascular & Hematological Disorders Genistein: A Phytoestrogen with Multifaceted Therapeutic Properties
Mini-Reviews in Medicinal Chemistry Clinical Presentation, Diagnostic Work-Up, and Treatment of Coronary In-Stent Restenosis
Vascular Disease Prevention (Discontinued) Resident and Non-Resident Stem Cells in Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets